Zika: Two Pieces of Bad News For the Price of One

By Josh Bloom —
As of now, all Zika infections that were transmitted by mosquitoes have been a result of the Aedes mosquito, which is found in warm areas. But now, the 800-pound pest in the room is whether the far more common Culex family of mosquitoes might be able to transmit the virus, which can make this issue more disturbing.

ZikaNEI have been writing about Zika since the time before it became part of the public vernacular. My first piece,"Zika is Possibly the Scariest Virus Since HIV," discussed a number of factors that would determine whether the virus was a real threat to the United States, or just another scare that ended up being nothing. There are far more cases of the latter than the former.

Perhaps the most important determinants of which way this goes is whether the virus could be transmitted by the common Culex family of mosquitoes, and how efficient this transmission would be. All cases to date have been due to the Aedes species of mosquito, which is uncommon in the U.S.

But this may change. Scientists have demonstrated that Culex quinquefasciatus, a mosquito that is 20-times more common than Aedes, can become infected with the virus, at least in a lab. This does not have to mean that the Culex family will play a significant part in transmission of the virus to large areas of the U.S., but it is nonetheless disturbing.

Speaking of disturbing, the following map from the Lancet gives a prediction (based on modeling) of the range of infection in the Americas if the Culex mosquito becomes a vector for Zika. There is nothing even remotely comforting about this. Roughly half of the U.S. would be at risk of contracting the infection. The yellow represents seasonal outbreaks, while the orange areas have a year-round risk. Keep in mind that modeling may or may not represent reality.

Zikamap

Next in this series: DDT vs. DEET. Facts that will surprise you.

 

Subscribe to our newsletter

Josh Bloom

Dr. Jonathan (Josh) Bloom, ACSH's Director of Chemical and Pharmaceutical Sciences, earned his Ph.D. at the University of Virginia and completed postdoctoral training at the University of Pennsylvania. During his 20-plus years in drug discovery at Wyeth, his research group discovered the antibiotic Tygacil®, approved in 2005. He holds 25 issued patents and has authored 35 academic papers. Since joining ACSH in 2010, he has written more than 2,000 articles and dozens of op-eds for major newspapers, including The Wall Street Journal and Chicago Tribune.

Recent articles by this author: